|本期目录/Table of Contents|

[1]胡晓菡,田新宇,沈瀚.肝细胞肝癌患者血清中成纤维细胞生长因子19表达对早期诊断的意义[J].医学研究与战创伤救治(原医学研究生学报),2020,22(5):473-476.[doi:10.3969/j.issn.1672-271X.2020.05.005]
　HU Xiao-han,TIAN Xin-yu,SHEN Han.The serological level of fibroblast growth factor-19 in hepatocarcinoma patients and its significance for early diagnosis of hepatocarcinoma[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(5):473-476.[doi:10.3969/j.issn.1672-271X.2020.05.005]
点击复制

肝细胞肝癌患者血清中成纤维细胞生长因子19表达对早期诊断的意义()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第22卷
期数:
2020年5期
页码:
473-476
栏目:
临床研究
出版日期:
2020-09-09

文章信息/Info

Title:
The serological level of fibroblast growth factor-19 in hepatocarcinoma patients and its significance for early diagnosis of hepatocarcinoma
作者:
胡晓菡; 田新宇; 沈瀚
作者单位：210008南京，南京大学医学院附属鼓楼医院检验科（胡晓菡、田新宇、沈瀚）
Author(s):
HU Xiao-han; TIAN Xin-yu; SHEN Han
(Department of Laboratory, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School，Nanjing 210008，Jiangsu, China)
关键词:
肝细胞肝癌; 成纤维细胞生长因子19; 酶联免疫吸附试验法; 肿瘤淋巴结远处转移分期; 肿瘤标志物
Keywords:
hepatocarcinoma;  fibroblast growth factor 19;  immunosorbent assay;  TNM;  tumor marker
分类号:
R735.7
DOI:
10.3969/j.issn.1672-271X.2020.05.005
文献标志码:
A
摘要:
目的探讨成纤维细胞生长因子19（FGF19）作为生物标志物在肝细胞肝癌患者早期诊断中的意义。方法收集2017年10月至2019年10月鼓楼医院经病理学确诊为肝细胞肝癌患者97例（肝细胞肝癌组），以及经实验室数据、临床表现和组织学诊断为慢性肝炎患者102例（慢性肝炎组），并选取同期健康人群73例作为健康对照组。收集每组人群的各项临床资料。采用酶联免疫吸附试验法（ELISA）测定3组受试者的血清FGF19水平。计算肝细胞肝癌组TNM不同病理分期(Ⅰ期、Ⅱ期、Ⅲ期及Ⅳ期)患者的FGF19水平。在肝细胞肝癌患者中将AFP与FGF19联合检测，观察其诊断效能的变化。结果3组研究对象在年龄、甲胎蛋白（AFP）、谷丙转氨酶（ALT）、谷草转氨酶（AST）、清蛋白（ALB）、血小板（PLT）方面比较，差异有统计学意义（P<0.05）；而性别、总胆红素（TBIL）及家族史比较,差异无统计学意义（P>0.05）。慢性肝炎组患者血清FGF19水平（57.62±4.66）pg/mL与健康对照组（49.83±5.79）pg/mL的差异无统计学意义（P>0.05）；而肝细胞肝癌组患者血清FGF19水平（122.55±13.28）pg/mL明显高于慢性肝炎组和健康对照组，差异具有统计学意义（P<0.05）。肝细胞肝癌Ⅰ期、Ⅱ期、Ⅲ期及Ⅳ期患者的FGF19水平分别为(89.5±12.2)、(103.9±6.9)、(133.9±22.5)及(152.6±26.8)pg/mL，与病理分期呈正相关（r=0.696,P<0.001）。在肝细胞肝癌组AFP中加入FGF19检测，敏感性从43.2%提高到69.7%。结论肝细胞肝癌患者血清FGF19水平明显增高，并且浓度随着病理分期增高而增加。显示FGF19可作为肝细胞肝癌的潜在肿瘤标志物，在其早期筛查和病情监测中具有重要意义。
Abstract:
ObjectiveTo investigate the level of fibroblast growth factor 19 (FGF19) as a serological biomarker in the early diagnosis of hepatocarcinoma (HCC).MethodsFrom October 2017 to October 2019，97 HCC patients and 102 patients with chronic hepatitis were diagnosed by pathology in Nanjing Drum Tower Hospital，and 73 healthy people in the same period were selected as the control group. The demographic and clinical characteristics were collected. The serum level of FGF19 was measured by enzyme-linked immunosorbent assay (ELISA). Besides，97 HCC patients were divided into four groups by pathological stages (stage Ⅰ,Ⅱ,Ⅲand Ⅳ). Detection of the diagnostic efficacy of FGF19 combined with AFP in HCC group.ResultsThe clinical data of the three groups were compared and found that there were significant differences in age，AFP，ALT，AST and ALB (P<0.05), but no significant differences in gender，TBIL and family history (P>0.05). There was no significant difference for FGF19 level (57.62±4.66) pg/mL between the patients with chronic hepatitis and healthy controls (49.83±5.79) pg/mL (P>0.05). However，the level of FGF19 (122.55±13.28) pg/mL in HCC patients was significantly higher than that in patients with chronic liver disease and healthy controls (P<0.05). The average level of FGF19 in stage Ⅰ, Ⅱ, Ⅲ and Ⅳ among HCC patients was (89.5±12.2),(103.9±6.9),(133.9±22.5) and (152.6±26.8) pg/mL，respectively, and positive correlation with pathological stage（r=0.696，P<0.001）. The sensitivity of FGF19 combing with AFP increased from 43.2% to 69.7%.ConclusionThe serological level of FGF19 in HCC patients is significantly increased，which is correlated with pathological stages of HCC. FGF19 may be a potential tumor marker of HCC，which might facilitate the early diagnosis and condition monitoring of HCC.

参考文献/References:

[1]李爱梅,孙一文,贾鹏,等.肝细胞源性肝癌PET-CT成像标准摄取值与葡萄糖转运蛋白1的关系[J].东南国防医药,2015,17(6):572-574，590.
[2]朱艳,夏芹芹,罗俊,等.甲胎蛋白、甲胎蛋白异质体与TNF-α因子联合检测在原发性肝癌诊断中的应用价值[J].临床和实验医学杂志,2020,19(4):383-386.
[3]林凯璇，穆洪，孙玉琳，等.肝细胞肝癌重要表面标志的表达和定位[J].医学研究生学报，2013，26（1）：4-8.
[4]Memon N，Griffin IJ，Lee CW，et al. Developmental regulation of the gut-liver (FGF19-CYP7A1) axis in neonates[J].J Matern Fetal Neonatal Med，2020，33(6):987-992.
[5]王磊,陈欣菊.FGF19/FGFR4信号通路在肝细胞癌中的研究进展[J].现代肿瘤医学,2019,27(16):2949-2954.
[6]唐雯华,刘顺芳,陈富平,等.肝癌预后相关生物标志物[J].肿瘤,2019,39(6):500-507.
[7]汪升蛟,宋正波,吕镗烽.术后IB期浸润性肺腺癌不同病理亚型的预后分析[J].东南国防医药,2019,21(3):234-239.
[8]Sawey ET，Chanrion M，Cai C，et al. Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening[J]. Cancer Cell,2011,19(3):347-358.
[9]侯婧瑛,凌辉,金小岩,等.lncRNA-MALAT1通过靶向下调miR-570-3p促进胃癌细胞增殖[J].中国病理生理杂志,2018,34(12):2145-2152.
[10]赵静静,戴小军,张晓春.Akt介导的信号通路在肿瘤淋巴管生成中的作用[J].肿瘤防治研究,2016,43(5):422-426.
[11]于文静,师盼,潘琼,等.胆汁淤积下FGF19-ERK通路可上调MRP3/4表达减轻肝细胞损伤[J].中国细胞生物学学报,2019,41(8):1588-1594.
[12]陈丹,王凯冰,李加桩,等.原发性肝癌的抗血管生成靶向治疗现状与挑战[J].中国肿瘤,2017,26(3):203-209.
[13]冯云,亢君君,方宗平,等.AZD4547促进自噬并促进索拉非尼耐药肝癌细胞的死亡[J].细胞与分子免疫学杂志,2019,35(4):339-343.
[14]卫晶,武希润.贝特类药物治疗原发性胆汁性胆管炎的研究现状[J].临床肝胆病杂志,2020,36(2):442-445.
[15]Repana D，Ross P. Targeting FGF19/FGFR4 Pathway:A Novel Therapeutic Strategy for Hepatocellular Carcinoma[J]. Diseases，2015,3(4):294-305.
[16]Gao L，Wang X，Tang Y，et al. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib[J]. J Exp Clin Cancer Res,2017,36(1):8.

相似文献/References:

[1]王金淳,杨 波,潘文琴,等.肝细胞肝癌MR DWI表现与病理学等级关系的分析[J].医学研究与战创伤救治(原医学研究生学报),2012,14(05):425.
　WANG Jin-chun,YANG Bo,PAN Wen-qin,et al.Retrospective analysis of the relationship between manifestation of MR DWI and histopathologic grade of primary hepatic carcinoma[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2012,14(5):425.
[2]陈晓杰,黄敬杨,翁亮,等.实时组织弹性成像技术对原发性肝细胞癌切除术后发生肝衰竭的价值分析[J].医学研究与战创伤救治(原医学研究生学报),2018,20(06):575.[doi:10.3969/j.issn.1672-271X.2018.06.004]
　CHEN Xiao-jie,HUANG Jing-yang,WENG Liang,et al.The study of real time tissue elastography for predicting the value of liver failure after hepatectomy in patients with primary hepatocellular carcinoma[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2018,20(5):575.[doi:10.3969/j.issn.1672-271X.2018.06.004]

备注/Memo

备注/Memo:
基金项目：江苏省“十三五科教强卫工程”医学重点人才项目（ZDRCA2016065）
更新日期/Last Update: 2020-09-09